217 related articles for article (PubMed ID: 18551040)
1. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.
Kohlrausch FB; Gama CS; Lobato MI; Belmonte-de-Abreu P; Callegari-Jacques SM; Gesteira A; Barros F; Carracedo A; Hutz MH
Pharmacogenet Genomics; 2008 Jul; 18(7):599-609. PubMed ID: 18551040
[TBL] [Abstract][Full Text] [Related]
2. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.
de Leon J; Susce MT; Pan RM; Koch WH; Wedlund PJ
J Clin Psychopharmacol; 2005 Oct; 25(5):448-56. PubMed ID: 16160620
[TBL] [Abstract][Full Text] [Related]
3. The polymorphisms of candidate pharmacokinetic and pharmacodynamic genes and their pharmacogenetic impacts on the effectiveness of risperidone maintenance therapy among Saudi children with autism.
Shilbayeh SAR; Adeen IS; Alhazmi AS; Aljurayb H; Altokhais RS; Alhowaish N; Aldilaijan KE; Kamal M; Alnakhli AM
Eur J Clin Pharmacol; 2024 Jun; 80(6):869-890. PubMed ID: 38421437
[TBL] [Abstract][Full Text] [Related]
4. The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study).
Kurylev AA; Brodyansky VM; Andreev BV; Kibitov AO; Limankin OV; Mosolov SN
Psychiatr Danub; 2018 Jun; 30(2):157-163. PubMed ID: 29930225
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
6. Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.
Ma L; Xiang Q; Zhao N; Hu C; Fang M; Tan Y; Chen S; Wang Z; Liu P; Sun K; Li Y; Wu F; Tian H; Fang M; Zhao X; Wang G; Cui Y
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110241. PubMed ID: 33400943
[TBL] [Abstract][Full Text] [Related]
7. Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium.
McGuire V; Van Den Eeden SK; Tanner CM; Kamel F; Umbach DM; Marder K; Mayeux R; Ritz B; Ross GW; Petrovitch H; Topol B; Popat RA; Costello S; Manthripragada AD; Southwick A; Myers RM; Nelson LM
J Neurol Sci; 2011 Aug; 307(1-2):22-9. PubMed ID: 21663922
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.
Fohner A; Muzquiz LI; Austin MA; Gaedigk A; Gordon A; Thornton T; Rieder MJ; Pershouse MA; Putnam EA; Howlett K; Beatty P; Thummel KE; Woodahl EL
Pharmacogenet Genomics; 2013 Aug; 23(8):403-14. PubMed ID: 23778323
[TBL] [Abstract][Full Text] [Related]
9. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
Ganoci L; Trkulja V; Živković M; Božina T; Šagud M; Lovrić M; Božina N
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110042. PubMed ID: 32682874
[TBL] [Abstract][Full Text] [Related]
10. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.
Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
Clin Pharmacol Ther; 2005 Nov; 78(5):551-8. PubMed ID: 16321621
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study.
Sáiz PA; García-Portilla MP; Arango C; Morales B; Arias B; Corcoran P; Fernández JM; Alvarez V; Coto E; Bascarán MT; Bousoño M; Fañanas L; Bobes J
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):26-31. PubMed ID: 19766158
[TBL] [Abstract][Full Text] [Related]
12. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study.
Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT
Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889
[TBL] [Abstract][Full Text] [Related]
13. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations.
Hwang R; Shinkai T; De Luca V; Müller DJ; Ni X; Macciardi F; Potkin S; Lieberman JA; Meltzer HY; Kennedy JL
Psychopharmacology (Berl); 2005 Aug; 181(1):179-87. PubMed ID: 15830237
[TBL] [Abstract][Full Text] [Related]
14. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
[TBL] [Abstract][Full Text] [Related]
15. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.
Malhotra AK; Goldman D; Buchanan RW; Rooney W; Clifton A; Kosmidis MH; Breier A; Pickar D
Mol Psychiatry; 1998 Jan; 3(1):72-5. PubMed ID: 9491816
[TBL] [Abstract][Full Text] [Related]
16. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia.
Basile VS; Masellis M; Badri F; Paterson AD; Meltzer HY; Lieberman JA; Potkin SG; Macciardi F; Kennedy JL
Neuropsychopharmacology; 1999 Jul; 21(1):17-27. PubMed ID: 10379516
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment.
van de Bilt MT; Prado CM; Ojopi EP; Sousa RT; Loch AA; Zanetti MV; Talib LL; Gattaz WF
Schizophr Res; 2015 Oct; 168(1-2):587-8. PubMed ID: 26298540
[TBL] [Abstract][Full Text] [Related]
18. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia.
Terzić T; Kastelic M; Dolžan V; Plesničar BK
Psychiatr Danub; 2016 Jun; 28(2):127-31. PubMed ID: 27287786
[TBL] [Abstract][Full Text] [Related]
20. European Multicentre Association Study of Schizophrenia: a study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms.
Spurlock G; Williams J; McGuffin P; Aschauer HN; Lenzinger E; Fuchs K; Sieghart WC; Meszaros K; Fathi N; Laurent C; Mallet J; Macciardi F; Pedrini S; Gill M; Hawi Z; Gibson S; Jazin EE; Yang HT; Adolfsson R; Pato CN; Dourado AM; Owen MJ
Am J Med Genet; 1998 Feb; 81(1):24-8. PubMed ID: 9514583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
